PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.01
D/E of 0.01 versus zero Biotechnology median. Walter Schloss would verify if our leverage provides competitive advantages.
3.31
Concerning net debt at 1.25-1.5x Biotechnology median of 2.49. Martin Whitman would look for hidden assets or restructuring potential.
No Data
No Data available this quarter, please select a different quarter.
1.37
Current ratio below 50% of Biotechnology median of 4.10. Michael Burry would check for immediate refinancing needs.
No Data
No Data available this quarter, please select a different quarter.